Breakthrough Shingles After Shingrix Vaccination
While breakthrough herpes zoster after Shingrix vaccination is rare, it does occur—the vaccine is 76% effective in real-world settings, meaning approximately 1 in 4 vaccinated individuals remain at risk for shingles. 1
Vaccine Efficacy and Breakthrough Rates
The FDA clinical trials demonstrated that Shingrix is highly effective but not perfect:
- 97.2% efficacy in adults ≥50 years in controlled trials 2
- Real-world effectiveness drops to 76% with 2 doses 1
- Among 7,344 vaccinated subjects aged ≥50, 6 breakthrough cases occurred over median 3.7 years of follow-up 2
- Among 6,541 vaccinated subjects aged ≥70, 23 breakthrough cases occurred 2
The key finding: breakthrough infections happen, but they are substantially less common than in unvaccinated individuals (0.3-0.9 per 1,000 person-years vs. 9.1-9.2 per 1,000 person-years in placebo groups) 2.
Clinical Characteristics of Breakthrough Cases
When breakthrough shingles occurs after Shingrix:
- Timing varies widely: Cases reported from 72 hours post-vaccination 3 to years later 4
- Severity may be reduced: Among breakthrough cases, only 43.5% required pain medication compared to 71.7% in unvaccinated individuals 2
- Postherpetic neuralgia risk is dramatically lower: Only 4 PHN cases among 8,250 vaccinated subjects vs. 36 cases among 8,346 placebo subjects aged ≥70 (88.8% reduction) 2
High-Risk Populations for Breakthrough Infection
Immunocompromised patients face higher breakthrough risk, particularly those on:
- JAK inhibitors: Case reports document breakthrough infections when JAK inhibitors are started after vaccination, as these drugs suppress the immune mechanisms underlying vaccine efficacy 4
- Corticosteroids: Vaccine effectiveness drops to 65% in patients receiving corticosteroids vs. 77% in those who don't 1
- Advanced immunosuppression: Patients with lymphoma and hypogammaglobulinemia remain vulnerable despite vaccination 5
Management Recommendations After Breakthrough Infection
If a vaccinated patient develops shingles, treat it as you would any herpes zoster case—the diagnosis and management don't change:
- Confirm diagnosis clinically (dermatomal vesicular rash with pain)
- Start antivirals within 72 hours: Standard acyclovir, valacyclovir, or famciclovir dosing
- Test for VZV DNA if presentation is atypical to distinguish true viral reactivation from vaccine-induced immune reactions 6
- Consider IV acyclovir for severe or disseminated cases, especially in immunocompromised patients 5
Vaccination After Breakthrough Infection
Guidelines recommend re-vaccination at least 2 months after a breakthrough shingles episode, as recurrence rates are substantial (10.3% cumulative incidence at 10 years) 7. The vaccine remains beneficial even after natural infection.
Critical Distinction: True Breakthrough vs. Vaccine-Induced Reactions
Rare zosteriform reactions can occur immediately post-vaccination that mimic shingles but may not represent true VZV reactivation 6:
- If lesions appear within days of vaccination and don't respond to antivirals, consider immune-mediated reaction
- VZV DNA testing is negative in these cases
- Short-term oral corticosteroids may be more effective than antivirals 6
Bottom Line for Clinical Practice
The occurrence of breakthrough shingles doesn't represent vaccine failure—it demonstrates partial protection. The vaccine significantly reduces both the incidence and severity of shingles, with the most dramatic benefit being an 88.8% reduction in postherpetic neuralgia 2. Breakthrough cases should be treated promptly with antivirals, and patients should still receive their second dose if they've only had one (unless the reaction was severe and temporally related to vaccination).